CSL Limited (ASX: CSL) is Australia’s largest (and some might say best) healthcare company, specialising in biopharmaceuticals. Founded in the late 1900s as the Commonwealth Serum Laboratories, CSL was sold by the Australian Government to Australian investors via the share market in 1994 at $2.30 per share, at which time it doubled its size through an international acquisition. CSL is a global leader in blood plasma vaccines (think: the flu) and antivenoms, providing relief for potentially life-threatening medical conditions.
Australia’s share market, or the All Ordinaries Index (INDEXASX: XAO)(ASX: XAO), is up by 0.28% at lunch.
The S&P/ASX 200 (INDEXASX: XJO) (^AXJO) and All Ordinaries (INDEXASX: XAO)(^AORD) indices ended slightly higher on Monday as ASX bank shares and CSL Limited (ASX: CSL) lifted the ASX 200.
Australia’s share market, or the All Ordinaries Index (INDEXASX: XAO)(ASX: XAO), is down by 0.26% at lunch.
Australia’s share market, or the All Ordinaries Index (INDEXASX: XAO)(ASX: XAO), is down by 0.59% at lunch.
Australia’s share market, or the All Ordinaries Index (INDEXASX: XAO)(ASX: XAO), is up by 0.58% at lunch.
The Australian share market, or S&P/ASX 200 (INDEXASX:XJO)(ASX:XJO), is expected to open higher on Thursday.
CSL Limited (ASX:CSL) tried its best to inject some enthusiasm into Australia’s S&P/ASX 200 (INDEXASX:XJO) (ASX:XJO) on Wednesday.
Australia’s share market, or the All Ordinaries (INDEXASX: XAO)(ASX: XAO), has fallen by 0.13% at lunch.
Immunology giant CSL Limited (ASX:CSL) reported its half-year results on Wednesday and investors loved it.
